Literature DB >> 2670602

Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment.

T J Walsh1, D M Dixon.   

Abstract

The purpose of this review is to characterize the environmental microbiology, hospital epidemiology, diagnosis and treatment of nosocomial aspergillosis. Appropriate environmental control measures are important in preventing or arresting an outbreak of nosocomial aspergillosis. These include selective environmental microbiological surveillance and floor to ceiling barriers during construction or renovation. These is particularly important for the bone marrow transplant units and units with persistently granulocytopenic patients. We have summarized the point source and cited or formulated the environmental correction measures relating to 25 outbreaks of nosocomial aspergillosis involving a total of more than 100 patients. The most frequent settings of nosocomial invasive aspergillosis occurred in granulocytopenic patients following respiratory infection from an airborne source, associated with hospital construction or contaminated ventilation systems.

Entities:  

Mesh:

Year:  1989        PMID: 2670602     DOI: 10.1007/bf00156818

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  74 in total

1.  Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital.

Authors:  J Aisner; S C Schimpff; J E Bennett; V M Young; P H Wiernik
Journal:  JAMA       Date:  1976-01-26       Impact factor: 56.272

2.  Experience with itraconazole in deep mycoses in northern Italy.

Authors:  M A Viviani; A M Tortorano; R Woenstenborghs; G Cauwenbergh
Journal:  Mykosen       Date:  1987-05

3.  Infections in hematologic malignancy.

Authors:  T R Rogers
Journal:  Infect Control       Date:  1986-02

4.  Fungal burn wound infection.

Authors:  G Nash; F D Foley; M N Goodwin; H M Bruck; K A Greenwald; B A Pruitt
Journal:  JAMA       Date:  1971-03-08       Impact factor: 56.272

5.  Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.

Authors:  S L Gerson; G H Talbot; S Hurwitz; B L Strom; E J Lusk; P A Cassileth
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

6.  Pseudoepidemic of aspergillosis after development of pulmonary infiltrates in a group of bone marrow transplant patients.

Authors:  J J Weems; A Andremont; B J Davis; C H Tancrede; M Guiguet; A A Padhye; F Squinazi; W J Martone
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

7.  Primary cutaneous aspergillosis associated with Hickman intravenous catheters.

Authors:  M D Allo; J Miller; T Townsend; C Tan
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

8.  Invasive nosocomial pulmonary aspergillosis: risk factors and hospital building works.

Authors:  M Perraud; M A Piens; N Nicoloyannis; P Girard; M Sepetjan; J P Garin
Journal:  Epidemiol Infect       Date:  1987-10       Impact factor: 2.451

9.  Primary cutaneous aspergillosis in six leukemic children.

Authors:  M E Grossman; E C Fithian; C Behrens; J Bissinger; M Fracaro; H C Neu
Journal:  J Am Acad Dermatol       Date:  1985-02       Impact factor: 11.527

10.  Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients.

Authors:  T J Walsh; D B Hier; L R Caplan
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

View more
  32 in total

1.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

2.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

3.  Fungicidal activity of cecropin A.

Authors:  A J DeLucca; J M Bland; T J Jacks; C Grimm; T E Cleveland; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

4.  N-acetylcysteine inhibits germination of conidia and growth of Aspergillus spp. and Fusarium spp.

Authors:  A J De Lucca; T J Walsh; D J Daigle
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air.

Authors:  K Anderson; G Morris; H Kennedy; J Croall; J Michie; M D Richardson; B Gibson
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

6.  Epidemiology of nosocomial fungal infections.

Authors:  S K Fridkin; W R Jarvis
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 7.  Diagnosis of invasive mycoses in severely immunosuppressed patients.

Authors:  R Rüchel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

8.  Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings.

Authors:  V Chazalet; J P Debeaupuis; J Sarfati; J Lortholary; P Ribaud; P Shah; M Cornet; H Vu Thien; E Gluckman; G Brücker; J P Latgé
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

9.  Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis.

Authors:  M C Allende; J W Lee; P Francis; K Garrett; H Dollenberg; J Berenguer; C A Lyman; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  A study on Aspergillus species in houses of asthmatic patients from Sari City, Iran and a brief review of the health effects of exposure to indoor Aspergillus.

Authors:  Mohammad T Hedayati; Sabah Mayahi; David W Denning
Journal:  Environ Monit Assess       Date:  2009-08-21       Impact factor: 2.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.